Silence Therapeutics
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
Development
Silence Therapeutics develops medicines related to RNA interference or RNAi to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD platform can be used to create siRNAs that target and silence disease-associated genes in the liver.Silence Therapeutic's product candidates include SLN124 for hematological diseases and zerlasiran for reducing cardiovascular risk in people born with high levels of lipoprotein(a), a genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp by up to 99 per cent for 90 days after.